山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (9): 125-128.doi: 10.6040/j.issn.1671-7554.0.2022.0080
孙文雄1,吴日超2,郑贤静3,李丽4, 张友忠1
中图分类号:
| [1] Hornick JL, Fletcher CD. PEComa: what do we know so far?[J]. Histopathology, 2006, 48(1): 75-82. [2] Kallen ME, Hornick JL. The 2020 WHO classification: whats new in soft tissue tumor pathology?[J]. Am J Surg Pathol, 2021, 45(1): e1-e23. [3] Fadare O. Perivascular epithelioid cell tumor(PEComa)of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases[J]. Adv Anat Pathol, 2008, 15(2): 63-75. [4] Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms[J]. Hum Pathol, 2007, 38(9): 1361-1371. [5] Kovac O, Babal P, Kajo K, et al. Perivascular epithelioid cell tumor(PEComa)of the uterine cervix: a case report of a 43-yr-old woman with abnormal utering treated with hysterectomy[J]. Int J Gynecol Pathol, 2018, 37(5): 492-496. [6] Bennett JA, Braga AC, Pinto A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors[J]. Am J Surg Pathol, 2018, 42(10): 1370-1383. [7] Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature[J]. Am J Surg Pathol, 2005, 29(12): 1558-1575. [8] Bennett JA, Ordulu Z, Pinto A, et al. Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions[J]. Mod Pathol, 2022, 35(4): 515-523. [9] Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms(PEComas): a clinicopathological study emphasizing extrarenal PEComas[J]. Histopathology, 2013, 62(4): 642-650. [10] Valencia-Guerrero A, Pinto A, Anderson WJ, et al. PNL2: a useful adjunct biomarker to HMB45 in the diagnosis of uterine perivascular epithelioid cell tumor(PEComa)[J]. Int J Gynecol Pathol, 2020, 39(6): 529-536. [11] Stone JL, Batty T, Nicklin J. Cervical perivascular epithelioid cell tumour(PEComa)of the uterine cervix: cytological findings in a cervical smear[J]. Cytopathology, 2013, 24(4): 272-273. [12] Tajima S, Koda K. Perivascular epithelioid cell tumor of the uterine cervix identified on a conventional cervical smear[J]. Diagn Cytopathol, 2015, 43(12): 1011-1016. [13] Zhang C, Pan F, Qiao J, et al. Perivascular epithelioid cell tumor of the cervix with malignant potential[J]. Int J Gynaecol Obstet, 2013, 123(1): 72-73. [14] Sanfilippo R, Jones RL, Blay JY, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors(PEComas)[J]. Clin Cancer Res, 2019, 25(17): 5295-5300. [15] Le P, Garg A, Brandao G, et al. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma[J]. Curr Oncol, 2014, 21(3): e518-e520. [16] Chiang S, Vasudevaraja V, Serrano J, et al. TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition[J]. Mod Pathol, 2022, 35(1): 117-127. [17] Wagner AJ, Ravi V, Riedel RF, et al. nab-sirolimus for patients with malignant perivascular epithelioid cell tumors[J]. J Clin Oncol, 2021, 39(33): 3660-3670. [18] Gu X, Yu JJ, Ilter D, et al. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis[J]. Proc Natl Acad Sci U S A, 2013, 110(37): 14960-14965. [19] Sanfilippo R, Fabbroni C, Fucà G, et al. Addition of antiestrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors[J]. Clin Cancer Res, 2020, 26(20): 5534-5538. [20] McBride A, Garcia AJ, Sanders LJ, et al. Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report[J]. J Med Case Rep, 2021, 15(1): 400. [21] 陈筱莉,蹇顺海,杨慧敏,等.伴TFE3基因易位的子宫颈PEComa 1例并文献复习[J].重庆医学, 2020, 49(21): 3569-3573. CHEN Xiaoli, JIAN Shunhai, YANG Huimin, et al. Cervical perivascular epithelioid cell tumor with TFE3 gene translocation: a case report and literature review [J]. Chongqing Medicine, 2020, 49(21): 3569-3573. |
| [1] | 巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-. |
| [2] | 孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62. |
| [3] | 林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124. |
| [4] | 樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23. |
| [5] | 李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76. |
| [6] | 国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32. |
| [7] | 赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 131I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28. |
| [8] | 韩馨玮,牛月,魏代敏. 激素替代方案准备内膜的冻胚移植前雌激素治疗时间对新生儿体质量的影响[J]. 山东大学学报 (医学版), 2025, 63(11): 46-52. |
| [9] | 黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12. |
| [10] | 薛铭,梁静,凌斌. 各种类型子宫内膜异位症疼痛特点及治疗研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 13-19. |
| [11] | 山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16. |
| [12] | 宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59. |
| [13] | 刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72. |
| [14] | 陈忠,王盛. 主动脉疾病治疗现状及思考[J]. 山东大学学报 (医学版), 2024, 62(9): 1-6. |
| [15] | 范立彬,张鸿坤. 腹主动脉瘤腔内修复术后Ⅱ型内漏的预防及治疗进展[J]. 山东大学学报 (医学版), 2024, 62(9): 55-60. |
|
||
